Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://data.mendeley.com/datasets/79dp7449jw
下载链接
链接失效反馈官方服务：
资源简介：
Supplement 1: Report of Cases
Seven patients were prescribed dupilumab for chronic recalcitrant presumed AD (cases 1-4), or as an off-label treatment for patients with MF and severe pruritus (cases 5-7). In all 7 patients, the standard dosing regimen for dupilumab was followed (600mg loading dose, followed by 300mg every 2 weeks subcutaneously).
Case vignettes and photographs found below.
创建时间：
2020-03-19
